Xalkori® 解碼康®

Xalkori®  解碼康®  是⼀種美國食品藥品監督管理局認可的⼀線⼝服標靶藥物。Xalkori®解碼康®專⾨針對擁有ALK和ROS-1基因突變的肺細胞1。在本港已被撒瑪利亞基⾦納入為針對⼀種病症的受資助藥物，協助有需要⼈⼠踏上治療成功之路2。

 

參考資料：

  1. Xalkori® (crizotinib) Prescribing Information. Pfizer Corporation Hong Kong Limited:Version August 2018.
  2. Information for Samaritan Fund & Community Care Fund Medical Assistance Programmes–Application for Drug Items. Hong Kong Hospital Authority. Available at http://www.ha.org.hk/haho/ho/sf/Capping_leaflet_en.pdf. Accessed on 6 June 2019.

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: 
標靶治療 Targeted Therapy